Pharma Companies May Get Time Till December To Comply With Schedule M Norms

New Delhi:  The government is likely to give an extension till December this year to the drug manufacturers to implement revised Schedule M, people aware of the matter told ET.

The drug rules will subsequently be amended to provide the extension of time, they said. Once the final notification is published-which is expected this week-the manufacturers will be asked to fill an application with ten drug regulatory authorities detailing the strategy on how they will comply within the prescribed timeline.

As per ET, the health ministry had sought the legal affairs department’s view on its final draft notification on allowing small pharmaceutical companies more time for upgrading their facilities to comply with the revised Schedule M.

Schedule M of the Drugs and Cosmetics Act outlines quality standards for pharmaceutical products. The revised Scheduled M standards  were notified in January last year. While units with annual turnover of more than Rs 250 crore had to comply from July 1, 2023, the implementation date for MSMEs was January 1 this year. However, the MSMEs had sought more time to make the necessary changes in their manufacturing processes. The ministry then issued a draft notification proposing to extend the deadline for the MSMEs. In this regard, it had invited public comments by January 11. “The feedback was compiled and the final draft has been sent to the legal affairs department for vetting,” one of the people cited earlier told ET. The country’s pharma lobby groups have been seeking a two-year extension to the deadline, saying that much time is needed for improving infrastructure, increasing manpower and training.

SOURCE : Economic Times

  • Related Posts

    • Pharma
    • March 13, 2025
    • 99 views
    Indian generic drugs linked to deaths in US? Trade group slams study blaming desi pharma

    A study linking Indian-made generic drugs to a higher risk of serious side effects in the US has drawn backlash from the industry’s most influential lobby group, as India moves…

    • Pharma
    • March 13, 2025
    • 84 views
    Indian Pharma market to expand by 8-9 percent in FY 26: Report

    New Delhi: Indian pharmaceutical market is projected to see a growth of 8-9 per cent year-on-year in FY26 as per the recent report by India Ratings and Research (Ind-Ra). The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Indian generic drugs linked to deaths in US? Trade group slams study blaming desi pharma

    Indian generic drugs linked to deaths in US? Trade group slams study blaming desi pharma

    Indian Pharma market to expand by 8-9 percent in FY 26: Report

    Indian Pharma market to expand by 8-9 percent in FY 26: Report

    India’s Pharma Exports Face Tariff Hurdle amidst Trade Talks with the U.S.

    India’s Pharma Exports Face Tariff Hurdle amidst Trade Talks with the U.S.

    ED arrests two for trafficking banned drugs to US citizens

    ED arrests two for trafficking banned drugs to US citizens